US 12,290,509 B2
Treatment of hepatitis delta virus infection
David A. Cory, Palo Alto, CA (US); Ingrid Choong, Palo Alto, CA (US); and Jeffrey S. Glenn, Palo Alto, CA (US)
Assigned to EIT Pharma, Inc., Los Angeles, CA (US)
Filed by EIT Pharma, Inc., Los Angeles, CA (US)
Filed on Sep. 15, 2023, as Appl. No. 18/467,858.
Application 18/467,858 is a continuation of application No. 17/655,470, filed on Mar. 18, 2022, granted, now 11,793,793.
Application 17/655,470 is a continuation of application No. 16/996,147, filed on Aug. 18, 2020, granted, now 11,311,519, issued on Apr. 26, 2022.
Application 16/996,147 is a continuation of application No. 16/052,386, filed on Aug. 1, 2018, granted, now 10,828,283, issued on Nov. 10, 2020.
Application 16/052,386 is a continuation of application No. 15/335,327, filed on Oct. 26, 2016, granted, now 10,076,512, issued on Sep. 18, 2018.
Application 15/335,327 is a continuation in part of application No. PCT/US2015/028933, filed on May 1, 2015.
Claims priority of provisional application 62/151,349, filed on Apr. 22, 2015.
Claims priority of provisional application 62/073,413, filed on Oct. 31, 2014.
Claims priority of provisional application 62/044,766, filed on Sep. 2, 2014.
Claims priority of provisional application 61/987,315, filed on May 1, 2014.
Claims priority of provisional application 62/321,623, filed on Apr. 12, 2016.
Claims priority of provisional application 62/297,740, filed on Feb. 19, 2016.
Claims priority of provisional application 62/251,026, filed on Nov. 4, 2015.
Prior Publication US 2024/0277676 A1, Aug. 22, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/427 (2006.01); A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 31/4545 (2006.01); A61K 38/21 (2006.01); A61K 47/60 (2017.01)
CPC A61K 31/427 (2013.01) [A61K 9/0053 (2013.01); A61K 9/146 (2013.01); A61K 31/4545 (2013.01); A61K 38/21 (2013.01); A61K 38/212 (2013.01); A61K 47/60 (2017.08)] 20 Claims
 
1. A method of treating a human patient having a hepatitis delta virus (HDV) infection, the method comprising administering to the patient a therapeutically effective dose of lonafarnib and a therapeutically effective dose of ritonavir.